Argenx
ARGX
#397
Rank
HK$509.74 B
Marketcap
HK$8,148
Share price
0.16%
Change (1 day)
53.92%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): HK$123.35

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$123.89. In 2025 the company made an earnings per share (EPS) of HK$165.19 an increase over its 2024 EPS that were of HK$109.08.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$123.35-25.33%
2025HK$165.1951.44%
2024HK$109.08-369.77%
2023-HK$40.43-60.46%
2022-HK$102.2663.33%
2021-HK$62.61-40.37%
2020-HK$105.01183.47%
2019-HK$37.04123.09%
2018-HK$16.6054.93%
2017-HK$10.7214.07%
2016-HK$9.4013.05%
2015-HK$8.31-36.34%
2014-HK$13.05209.04%
2013-HK$4.22-33.99%
2012-HK$6.40185.59%
2011-HK$2.24